---
title: restrictive and infiltrative cardiomyopathy
date: "2023-01-18"
enableToc: false
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[cardiomyopathies]]

# restrictive and infiltrative cardiomyopathy

## [[definition of restrictive and infiltrative cardiomyopathy]] (JACC 2018;71:1130 & 1149)

## Etiologies (JACC 2018;71:1130 & 1149)

- [[amyloidosis]]: age at presentation ~60 y; â™‚:â™€ = 3:2

AL (eg, MM, etc.); familial (transthyretin, ATTR-m); senile (ATTR-wt)

ECG: â†“ QRS amplitude (50%), pseudoinfarction pattern (Qw), AVB (10â€“20%), hemiblock (20%), BBB (5â€“20%)

Echo: biventricular wall thickening (yet w/ low voltage on ECG), granular sparkling (30%), biatrial enlargement (40%), valve thickening, small effusions

Normal ECG voltage & septal thickness has NPV ~90%

Cardiac MRI: distinct late gadolinium enhancement pattern (JACC 2008;51:1022)

- Sarcoidosis (can also be DCM): presents at age ~30 y; â†‘ in blacks, N. Europe, â™€

Cardiac involvement in 25â€“58% of sarcoid, many not overt; cardiac w/o systemic in 10%

ECG: AVB (75%), RBBB (20â€“60%), VT; PET: â†‘ FDG uptake in affected area

Echo: regional WMA (particularly basal septum) w/ thinning or mild hypertrophy

Cardiac MRI: T2 early gad (edema); fibrosis/scar in basal septum; LGE prognostic

- Other myocardial processes

Hemochromatosis: often middle-aged men (espec N. European); 15% w/ cardiac sx

Diabetes; radiation (also accelerated athero, valvular disease, constrictive pericarditis)

Autoimmune (scleroderma, polymyositis-dermatomyositis)

- Endomyocardial diseases: carcinoid heart disease (R-sided HF w/ TR/TS, PR/PS); LÃ¶fflerâ€™s endocarditis (â†‘ eos; mural thrombi that can embolize; fibrosis); endomyocardial fibrosis (tropical climates; resembles LÃ¶fflerâ€™s but w/o eos)

- Storage diseases: Fabry (glycosphingolipids); Gaucher (glucocerebrosidase)

Pathophysiology

- â†“ myocardial compliance â†’ nl EDV but â†‘ EDP â†’ â†‘ systemic & pulm. venous pressures

- â†“ ventricular cavity size â†’ â†“ SV and â†“ CO

Clinical manifestations (JACC 2018;71:1130 & 1149)

- Right-sided >left-sided heart failure with peripheral edema >pulmonary edema

- Diuretic â€œrefractorinessâ€; thromboembolic events

- Poorly tolerated tachyarrhythmias; VT â†’ syncope/sudden cardiac death

Physical exam

- â†‘ JVP, Â± Kussmaulâ€™s sign (JVP not â†“ w/ inspir., classically seen in constrict. pericarditis)

- Cardiac: Â± S3 and S4, Â± murmurs of MR and TR

- Congestive hepatomegaly, Â± ascites and jaundice, peripheral edema

Diagnostic studies

- CXR: normal ventricular chamber size, enlarged atria, Â± pulmonary congestion

- ECG: low voltage, pseudoinfarction pattern (Qw), Â± arrhythmias

- Echo: Â± symmetric wall thickening, biatrial enlarge., Â± mural thrombi, Â± cavity oblit. w/ diast dysfxn: â†‘ early diast (E) and â†“ late atrial (A) filling, â†‘ E/A ratio; â†“ mitral annular velocity (eâ€²) on tissue Doppler, â†‘ E/eâ€² ratio

- Cardiac MRI/PET: may reveal inflammation or evidence of infiltration (but nonspecific)

- Amyloid (qv) workup: âœ“ for plasma cell dyscrasia (immunofix. & serum free light chains). If âŠ• â†’ fat pad bx. If âŠ– â†’ PYP SPECT for TTR evaluation (not AL).

- Endomyocardial biopsy if suspect amyloid (Se ~100%) & noninvasive tests non-dx. Se low for sarcoidosis b/c patchy disease infiltrative process.

- Cardiac catheterization

Atria: Mâ€™s or Wâ€™s (prominent x and y descents)

Ventricles: dip & plateau (rapid â†“ pressure at onset of diastole, rapid â†‘ to early plateau)

Concordance of LVâ€“RV pressure peaks w/ respiration (vs. discordance in constriction)

- Restrictive cardiomyopathy vs. constrictive pericarditis: see â€œPericardial Diseaseâ€

Treatment (in addition to Rxâ€™ing underlying disease)

- Gentle diuresis. May not tolerate CCB or other vasodilators.

- Control HR (but can â†“ CO); maintain SR (helps filling). Digoxin â†‘ arrhythmias in amyloid.

- Anticoagulation (particularly with AF or low CO)

- Transplantation for refractory cases

- AL amyloid: Rx targeted at plasma cell dyscrasia

- ATTR amyloid: tafamidis (TTR binder) â†“ death and CV hosp, â†‘QoL (NEJM 2018;379:1007)

- Sarcoid: consider steroids/immunomodulators if FDG PET âŠ• for inflammation + AVB, VT or LV dysfxn; â†‘ risk for VT; unique indications for ICD placement (Circ 2018;138:e272)
